CDK4 and breast neoplasm: Collectively, these data indicated that XBP1s is highly expressed in HR+/HER2− breast tumors and exhibits a significant correlation with poor prognosis and resistance to the combination of CDK4/6 inhibitors and endocrine therapy in these patients.